Ambrx to Present Preliminary ARX517 First-in-Human Safety, Efficacy, and Pharmacokinetics Data at ESMO 2023
July 28, 2023 08:30 ET
|
Ambrx Biopharma Inc.
SAN DIEGO, July 28, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., Ambrx (or the “Company”) (NASDAQ: AMAM), today announced the acceptance of four abstracts for poster presentation at the European...
FDA Grants Fast Track Designation for Ambrx’s ARX517 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
July 19, 2023 09:03 ET
|
Ambrx Biopharma Inc.
SAN DIEGO, July 19, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., Ambrx (or the “Company”) (NASDAQ: AMAM), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track...
Ambrx Announces Closing of $75 Million Market Priced Registered Offering
June 28, 2023 08:30 ET
|
Ambrx Biopharma Inc.
SAN DIEGO, June 28, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (or the “Company”) (NASDAQ: AMAM), today announced the closing of its previously announced market-priced registered direct...
Ambrx Appoints Jared Kelly as General Counsel
June 05, 2023 08:30 ET
|
Ambrx Biopharma Inc.
SAN DIEGO, June 05, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (NASDAQ: AMAM), today announced the appointment of Jared Kelly as Senior Vice President, General Counsel and Corporate...
Ambrx to Present at Multiple Upcoming Investor Meetings
May 30, 2023 09:01 ET
|
Ambrx Biopharma Inc.
SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (or the “Company”) (NASDAQ: AMAM), today announced that Daniel J. O’Connor, Chief Executive Officer and President of Ambrx,...
Ambrx Announces $75 Million Market Priced Registered Offering
May 24, 2023 08:30 ET
|
Ambrx Biopharma Inc.
SAN DIEGO, May 24, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (or the “Company”) (NASDAQ: AMAM), today announced that it has entered into a securities purchase agreement with clients...
Ambrx Appoints Stephen Glover as Chairman of its Board of Directors
May 18, 2023 16:05 ET
|
Ambrx Biopharma Inc.
SAN DIEGO, May 18, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (NASDAQ: AMAM), today announced that Stephen Glover has joined the Company’s Board of Directors as Chairman. Mr. Glover has...
Ambrx to Present at JMP Securities Life Sciences and RBC Capital Markets Global Healthcare Conferences
May 11, 2023 16:23 ET
|
Ambrx Biopharma Inc.
SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (NASDAQ: AMAM), today announced that Daniel J. O’Connor, Chief Executive Officer and President of Ambrx, will present a...
Ambrx Expands Leadership Team with Appointment of Andrew Aromando as Chief Operating Officer
May 04, 2023 16:05 ET
|
Ambrx Biopharma Inc.
SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (NASDAQ: AMAM), today announced the appointment of Andrew P. Aromando as Chief Operating Officer. Mr. Aromando brings over...
Ambrx Presents New Preclinical Data on ARX517 and ARX305 at the 2023 AACR Annual Meeting
April 19, 2023 09:00 ET
|
Ambrx Biopharma Inc.
SAN DIEGO, April 19, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (NASDAQ: AMAM), announced new preclinical data at the 2023 American Association for Cancer Research (AACR) Annual Meeting...